COMPARISON OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS FOR THE TREATMENT OF CORONARY ARTERY DISEASE

I AHMAD; R ULLAH; S KUMAR; AA TIPU; M EJAZ; A AZIZ; F HASAN; FM SHARFI; S REHMAN

doi:10.54112/bcsrj.v2024i1.1146

Authors

I AHMAD Department of Cardiology, Timergara Teaching Hospital, Timergara Dir Lower, Pakistan
R ULLAH Department of Medicine, Akbar Medical Center Peshawar, Pakistan
S KUMAR Department of Cardiology, National Institute of Cardiovascular Diseases Karachi, Pakistan
AA TIPU Department of Cardiology, Chaudhary Pervaiz Elahi Institute of Cardiology, Wazirabad, Pakistan
M EJAZ Department of Cardiology, Ayub Teaching Hospital Abbottabad, Pakistan
A AZIZ Department of General Medicine, Waqar Clinic, Fateh Jang, Pakistan
F HASAN Dow University of Health Sciences, Karachi, Pakistan
FM SHARFI Jinnah Sindh Medical University, Karachi, Pakistan
S REHMAN Department of Pharmaceutical Sciences, Lahore University of Applied and Biological Sciences, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1146

Keywords:

Coronary Artery Disease Percutaneous Coronary Intervention Drug-Eluting Stents Bare-Metal Stents Myocardial Infarction

Abstract

Coronary artery disease is a condition that affects millions of people worldwide and can lead to serious complications such as heart attack or stroke. Objectives: The study compares drug-eluting stents to bare-metal stents for treating coronary artery disease. Methods: The present study aimed to compare the efficacy and safety of drug-eluting stents (1) versus bare metal stents (BMS) for the treatment of coronary artery disease (CAD). The study was conducted at Cardiology Department Hayat Abad Medical Complex Peshawar Pakistan, from 01 January 2022 till 30 June 2022. The study included a total of 384 patients with CAD who underwent percutaneous coronary intervention (PCI) with either DES or BMS. Results: The study included a total of 384 patients with CAD who underwent PCI with either DES or BMS. The mean age of the study participants was 58.2 ± 9.4 years, and 75.8% were male. The baseline characteristics, including demographic data, clinical presentation, cardiovascular risk factors, and angiographic findings, were comparable between the two groups. Conclusion: In conclusion, our study contrasting medication-eluting stents versus exposed metal stents for the treatment of coronary supply route sickness found that drug-eluting stents were related to a lower chance of unfriendly heart occasions, including objective vessel revascularization, myocardial dead tissue, and cardiovascular demise, contrasted with uncovered metal stents.

Downloads

Download data is not yet available.

References

Singh IM, Filby SJ, El Sakr F, Gorodeski EZ, Lincoff AM, Ellis SG, et al. Drug‐eluting stents versus bare‐metal stents for treatment of bare‐metal in‐stent restenosis. 2010;76(2):257-62.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. 2012;125(23):2873-91.

Eltchaninoff H, Durand E, Avinée G, Tron C, Litzler P-Y, Bauer F, et al. Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. 2018;14(3):e264-e71.

Nordmann AJ, Briel M, Bucher HCJEhj. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. 2006;27(23):2784-814.

Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV. 2016;67(7):751-62.

Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. 2012;125(9):1110-21.

Doyle B, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. 2007;116(21):2391-8.

Bundhun PK, Bhurtu A, Soogund MZS, Long M-YJPO. Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 10 randomized controlled trials. 2016;11(4):e0154064.

Schühlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. 2004;147(2):317-22.

Lai C-H, Lee W-L, Sung S-H, Hsu P-F, Chen Y-H, Chan W-L, et al. Comparison of bare-metal stent and drug-eluting stent for the treatment of patients undergoing percutaneous coronary intervention for unprotected left main coronary artery disease–long-term result from a single center experience. 2015;31(5):381.

Liu L, Liu B, Ren J, Hui G, Qi C, Wang JJBcd. Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials. 2018;18:1-16.

Jia B, Zhang X, Ma N, Mo D, Gao F, Sun X, et al. Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial. 2022;79(2):176-84.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. 2009;151(4):W-65-W-94.

Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. 2009;360(19):1946-59